EcoDrugPlus

Cytochrome P450 Family 26 Subfamily A Member 1

Ensembl ID : ENSOKIG00005046690
Gene Symbol: CYP26A1
3 Cross references
132 Possible Orthologues:

Cytochrome P450, Family 17, Subfamily A, Polypeptide 1

Ensembl ID : ENSOKIG00005008708
Gene Symbol: CYP17A1
1 Cross references
210 Possible Orthologues:

Cytochrome P450, Family 19, Subfamily A, Polypeptide 1a

Ensembl ID : ENSOKIG00005035287
Gene Symbol: CYP19A1A
1 Cross references
244 Possible Orthologues:

Delta-Type Opioid Receptor

Ensembl ID : ENSOKIG00005022909
Gene Symbol: LOC109907398
2 Cross references
185 Possible Orthologues:

Delta-Type Opioid Receptor

Ensembl ID : ENSOKIG00005002433
Gene Symbol: LOC109865140
3 Cross references
128 Possible Orthologues:

Delta-Type Opioid Receptor

Ensembl ID : ENSOKIG00005047869
Gene Symbol: LOC109875874
3 Cross references
208 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSOKIG00005009627
Gene Symbol: LOC109870328
3 Cross references
207 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSOKIG00005032349
Gene Symbol: LOC109903108
3 Cross references
186 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSOKIG00005039859
Gene Symbol: DGAT1
1 Cross references
187 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSOKIG00005008229
Gene Symbol: LOC109903416
3 Cross references
184 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1-Like

Ensembl ID : ENSOKIG00005016352
Gene Symbol: LOC109907174
3 Cross references
184 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1b

Ensembl ID : ENSOKIG00005041713
Gene Symbol: DGAT1B
1 Cross references
187 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).